학술논문

299PThe prevalence of PIK3CA mutations in HR+/HER2– metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials).
Document Type
Article
Source
Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Subject
*METASTATIC breast cancer
*GENETIC mutation
*HORMONE receptors
Language
ISSN
0923-7534